Neuromod Devices, the technology company that specialises in medical devices for tinnitus treatment, has announced 19 new clinical partnerships to expand the availability of the Lenire tinnitus treatment device in Europe.
This latest expansion will significantly increase the number of clinics providing Lenire in Ireland, Spain, Italy, Belgium, Switzerland, Austria and the United Kingdom.
Tinnitus, which is commonly known as “ringing in the ears” is a neurological condition that causes the constant perception of noise when there is no source. Approximately 65 million people are living with tinnitus in Europe.
Jordon Thompson, Partner at Harley Street Hearing & Musicians' Hearing Services, a new clinical partner based in London, spoke about the impact that Lenire has had on the clinic’s tinnitus patients.
“We introduced Lenire into our practice nearly a year ago and with Neuromod’s support our team quickly built confidence in this advanced technology.” said Jordon Thompson. “We are already seeing successful outcomes that are helping patients manage tinnitus more effectively.”
Lenire® is a bimodal neuromodulation device which has been proven to provide lasting relief from tinnitus in multiple large-scale clinical trials. Lenire treats tinnitus through a combination of auditory and tongue stimulation that retrains the brain to significantly reduce tinnitus focus.
Lenire has been proven safe and effective in clinical trials in three large-scale clinical trials that featured more than 600 patients.1
Lenire’s most recent clinical trial, TENT-A3, was a controlled clinical trial that found Lenire was superior to sound-only, the trial’s control, for the majority of patients with bothersome tinnitus. Results from TENT-A3 were published in Nature Communications Medicine.1
Results from Lenire’s TENT-A1 and TENT-A2 clinical trials found that 84% of 517 participants reported relief from tinnitus that sustained for at least 12 months.1
Analysis of 220 real-world Lenire patients further validated Lenire’s effectiveness as a tinnitus treatment device. The analysis, a peer-reviewed and published paper in Nature Communications Medicine, showed that 91.5% of patients treated with Lenire had a clinically significant reduction in tinnitus after 12 weeks of treatment with Lenire.1
Lenire is now available through hearing and tinnitus care clinics across Europe.
FURTHER INFORMATION:
Tinnitus patients can find a nearby clinic and book an appointment by visiting www.lenire.com/find-a-clinic
References
1 Visit www.lenire.com/clinical-trials for references.
